Efficacy of ANT Deep Brain Stimulation in Drug-Resistant Epilepsy 

June 2, 2023

Article published by Physician’s Weekly

The Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE) trial demonstrated the efficacy of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) in patients with drug-resistant epilepsy (DRE). The Medtronic Registry for Epilepsy (MORE) aims to assess ANT DBS therapy’s safety and longer-term effectiveness in routine clinical practice. For a study, researchers presented the results of the MORE registry, focusing on seizure frequency, responder rate, quality of life, depression, and safety outcomes. 

MORE was an observational registry that collected both prospective and retrospective clinical data. The study included participants aged 18 and older with focal DRE from 25 centers in 13 countries. Patients were followed for a minimum of 2 years and assessed for seizure frequency (SF), responder rate (RR), health-related quality of life (measured using the Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes.